Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania.

@article{Keck2009LongtermSA,
  title={Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania.},
  author={Paul E. Keck and M{\'a}rcio C Versiani and Lewis E Warrington and Antony D. Loebel and Robert Lynn Horne},
  journal={The Journal of clinical psychiatry},
  year={2009},
  volume={70 6},
  pages={844-51}
}
OBJECTIVE To evaluate long-term safety and efficacy of ziprasidone. METHOD Subjects completing a 21-day placebo-controlled trial of ziprasidone in DSM-IV acute bipolar mania (N = 65) were enrolled in a 52-week open-label extension of flexibly dosed ziprasidone 40 to 160 mg/day, administered b.i.d. Three subjects had missing evaluations (N = 62) but still provided demographic data. Subpopulations with manic (N = 43) or mixed (N = 19) episodes, and with (N = 37) or without (N = 25) psychotic… CONTINUE READING